NervGen Pharma Corp.
NGEN
Last
$1.73
Day
-1.1%
1y
-47.4%
5y
-4.4%
52w
-72.2%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1233d
EMA 21
1.90
EMA 50
1.98
EMA 200
2.59
20d high
-24.9%
5y high
-72.2%
5y range
13th
Positions held
Your positionsNGEN isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$1.95
Stop
$1.58
Stop distance
8.7%
Target vs last
+12.7%
Fundamentals
| Market cap | $188.16M | Enterprise value | $101.37M | Trailing P/E | — | Forward P/E | -5.13 |
| PEG | — | Price / book | 15.11 | Beta | 0.82 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -7.6% | ROA | -37.7% | Debt / equity | — |
| Current ratio | 1.23 | Free cash flow | $38.39M | Analyst recommendation | strong_buy | Mean target | $10.00 |
| 52w high | $6.30 | 52w low | $1.58 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$29.2M | -$1.7M | -$26.9M | -$4.2M | -$9.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$12.2M | -$7.5M | -$6.4M | -$6.2M | -$6.5M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$44.1M | -$24.3M | -$22.4M | -$20.7M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$25.1M | -$25.2M | -$17.8M | -$23.0M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
Price (daily)
Full chart · RSI · MACD · patternsNGEN · daily-15.3% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin